Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in South Carolina: - Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in South Carolina: - Beaufort Memorial Hospital — Beaufort, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- MUSC Health Florence Medical Center — Florence, South Carolina
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in South Carolina: - Research Site — West Columbia, South Carolina
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in South Carolina: - St Francis Cancer Center — Greenville, South Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 2 Recruiting Academic/Other
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on tissue review. …
Sponsor: Medical University of South Carolina
NCT ID: NCT07743190
Sites in South Carolina: - Medical University of South Carolina Hollings Cancer Center, — Charleston, South Carolina
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in South Carolina: - Normunity Investigational Site — Charleston, South Carolina
NA Recruiting Network
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in South Carolina: - Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Laurens — Clinton, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Beaufort Memorial Hospital — Beaufort, South Carolina
- Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- McLeod Health — Florence, South Carolina